Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
This is the complete answer, not a partial one — the list is never padded.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Taylor Schreiber | $565,600 | $0 | $0 | $656,531 | $296,940 | $0 | $13,692 | $1,532,763 |
| Chief Executive Officer | ||||||||
| Arunthathy Nirmalini (Lini) Pandite | 502,980 | 0 | 0 | 197,746 | 211,252 | 0 | 20,667 | 932,645 |
| Chief Medical Officer | ||||||||
| Andrew Neill | 467,160 | 0 | 0 | 205,226 | 196,207 | 0 | 14,840 | 883,433 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Taylor Schreiber | $1,532,763 | — | — | — |
| Arunthathy Nirmalini (Lini) Pandite | 932,645 | — | — | — |
| Andrew Neill | 883,433 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Arunthathy Nirmalini (Lini) Pandite | RSU | 18,937 | — | $69,120 |
| Andrew Neill | RSU | 42,375 | — | 154,669 |
| Arunthathy Nirmalini (Lini) Pandite | RSU | 34,856 | — | 127,224 |
| Andrew Neill | RSU | 17,462 | — | 63,736 |
| Arunthathy Nirmalini (Lini) Pandite | RSU | 8,684 | — | 31,697 |
| Andrew Neill | RSU | 8,331 | — | 30,408 |
| Taylor Schreiber | Option | 171,928 | 9.41 | — |
| Taylor Schreiber | Option | 684,600 | 1.18 | — |
| Arunthathy Nirmalini (Lini) Pandite | Option | 1,447 | 7.43 | — |
| Arunthathy Nirmalini (Lini) Pandite | Option | 18,892 | 3.57 | — |
| Arunthathy Nirmalini (Lini) Pandite | Option | 48,412 | 10.09 | — |
| Arunthathy Nirmalini (Lini) Pandite | Option | 206,200 | 1.18 | — |
| Andrew Neill | Option | 1,389 | 7.43 | — |
| Andrew Neill | Option | 214,000 | 1.18 | — |
| Andrew Neill | Option | 18,918 | 3.57 | — |
| Andrew Neill | Option | 58,855 | 10.09 | — |
The objectives of the Compensation Committee’s compensation philosophy are to attract, retain, and motivate superior executive talent through providing incentives that reward the achievement of performance goals correlated to enhancing shareholder value and aligning the executive’s interests with those of shareholders through long-term incentives linked to specific performance.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | — |
| Anti-hedging | — |
| Anti-pledging | — |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-28 | 49,849,887 | 4,356,199 | 1,660 | 91.96% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-28 | 91.96%a |
a. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 7,500 / 10,000 / 10,000 |
| Stock ownership guideline | — |
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Shattuck Labs names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Shattuck Labs.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Precigen | 2025 | Patricia Poppe | $1,400,000 | $11,155,472 | $0 | $2,919,000 | $19,812,481 |
| 2 | Iteos Therapeutics | 2024 | Michel Detheux | 628,684 | 0 | 4,965,264 | 421,014 | 6,085,657 |
| 3 | ORIC Pharmaceuticals | 2025 | Jacob Chacko | 657,500 | 826,000 | 3,634,560 | 434,000 | 5,567,164 |
| 4 | Black Diamond Therapeutics | 2025 | Mark Velleca | 667,400 | 189,000 | 1,006,030 | 348,717 | 2,234,919 |
| 5 | Mersana Therapeutics | 2024 | Michael Huber | 632,500 | 133,635 | 518,044 | 322,575 | 1,613,754 |
| 6 | Shattuck Labs | 2025 | Taylor Schreiber | 565,600 | 0 | 656,531 | 296,940 | 1,532,763 |
| — | PMV Pharmaceuticals | — | — | — | — | — | — | not in coverage universe |
| — | CytomX Therapeutics | — | — | — | — | — | — | not in coverage universe |
| — | BioAtla | — | — | — | — | — | — | not in coverage universe |
| — | ALX Oncology | — | — | — | — | — | — | not in coverage universe |
| — | Gritstone bio | — | — | — | — | — | — | not in coverage universe |
| — | IGM Biosciences | — | — | — | — | — | — | not in coverage universe |
| — | HOOKIPA Pharma | — | — | — | — | — | — | not in coverage universe |
| — | Kezar Life Sciences | — | — | — | — | — | — | not in coverage universe |
| — | Precision BioSciences | — | — | — | — | — | — | not in coverage universe |
| — | Prelude Therapeutics | — | — | — | — | — | — | not in coverage universe |
| — | Century Therapeutics | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Shattuck Labs | not disclosed | Option 100 | not disclosed | Aon |
| ALX Oncology | not disclosed | not disclosed | not disclosed | not disclosed |
| BioAtla | not disclosed | not disclosed | not disclosed | not disclosed |
| Black Diamond Therapeutics | 95% | not disclosed | not disclosed | Aon Human Capital Solutions (Aon plc) |
| Century Therapeutics | not disclosed | not disclosed | not disclosed | not disclosed |
| CytomX Therapeutics | not disclosed | not disclosed | not disclosed | not disclosed |
| Gritstone bio | not disclosed | not disclosed | not disclosed | not disclosed |
| HOOKIPA Pharma | not disclosed | not disclosed | not disclosed | not disclosed |
| IGM Biosciences | not disclosed | not disclosed | not disclosed | not disclosed |
| Iteos Therapeutics | not disclosed | not disclosed | not disclosed | Radford |
| Kezar Life Sciences | not disclosed | not disclosed | not disclosed | not disclosed |
| Mersana Therapeutics | 85% | Options 75 · RSU 25 | not disclosed | Pearl Meyer & Partners, LLC |
| ORIC Pharmaceuticals | not disclosed | not disclosed | not disclosed | Aon |
| PMV Pharmaceuticals | not disclosed | not disclosed | not disclosed | not disclosed |
| Precigen | not disclosed | not disclosed | Yes — Relative TSR | Meridian Compensation Partners, LLC |
| Precision BioSciences | not disclosed | not disclosed | not disclosed | not disclosed |
| Prelude Therapeutics | not disclosed | not disclosed | not disclosed | not disclosed |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Taylor Schreiber | DEF 14A | 2026-04-08 | 0001193125-26-146293 | Section “Executive Compensation”. As printed: 1,532,763. Filing ↗machine: r2 · c27 · span 274803–274812 |
| 2 | Section 01, Arunthathy Nirmalini (Lini) Pandite | DEF 14A | 2026-04-08 | 0001193125-26-146293 | Section “Executive Compensation”. As printed: 932,645. Filing ↗machine: r4 · c27 · span 279148–279155 |
| 3 | Section 01, Andrew Neill | DEF 14A | 2026-04-08 | 0001193125-26-146293 | Section “Executive Compensation”. As printed: 883,433. Filing ↗machine: r6 · c27 · span 283449–283456 |
| 4 | Section 06, 2026 vote | Form 8-K | 2026-06-02 | 0001193125-26-253784 | Item 5.07 · say-on-pay result. As reported: 91.96% (votes for as printed: 49,849,887). Filing ↗ |
| 5 | Precigen, Section 10b CEO total | DEF 14A | 2026-04-09 | 0001004980-26-000020 | CEO total compensation as printed in Precigen's own proxy. As printed: 19,812,481. Filing ↗machine: t111 · r2 · c16 · span 1281710–1281720 |
| 6 | Iteos Therapeutics, Section 10b CEO total | DEF 14A | 2025-04-24 | 0000950170-25-057666 | CEO total compensation as printed in Iteos Therapeutics's own proxy. As printed: 6,085,657. Filing ↗machine: r2 · c27 · span 499272–499281 |
| 7 | ORIC Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186911 | CEO total compensation as printed in ORIC Pharmaceuticals's own proxy. As printed: 5,567,164. Filing ↗machine: r2 · c26 · span 435191–435200 |
| 8 | Black Diamond Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001104659-26-051474 | CEO total compensation as printed in Black Diamond Therapeutics's own proxy. As printed: 2,234,919. Filing ↗machine: r1 · c41 · span 370031–370040 |
| 9 | Mersana Therapeutics, Section 10b CEO total | DEF 14A | 2025-04-29 | 0001104659-25-040448 | CEO total compensation as printed in Mersana Therapeutics's own proxy. As printed: 1,613,754. Filing ↗machine: t16 · r1 · c41 · span 608188–608197 |
| 10 | Shattuck Labs (subject), Section 10b CEO total | DEF 14A | 2026-04-08 | 0001193125-26-146293 | CEO total compensation as printed in Shattuck Labs's own proxy. As printed: 1,532,763. Filing ↗machine: r2 · c27 · span 274803–274812 |
| 11 | Section 10a, Mersana Therapeutics reciprocity | DEF 14A | — | 0001104659-25-040448 | Mersana Therapeutics's most recent proxy was read; its disclosed peer group does not include Shattuck Labs. Filing ↗ |
| 12 | Section 10a, Precigen reciprocity | DEF 14A | — | 0001004980-26-000020 | Precigen's most recent proxy was read; its disclosed peer group does not include Shattuck Labs. Filing ↗ |